Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06568224
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-05-27
Brief Title:
Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Treatment for Hidradenitis Suppurativa
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Background Hidradenitis suppurativa HS is a chronic inflammatory relapsing disease involving the axillae breast groin and anogenital regions The therapies of the disease are diverse including medication and surgery However responses to treatments are variable and relapse is common with no single agent being consistently effective
Objective To evaluate the efficacy and safety of oral mesalazine treatment for hidradenitis suppurativa
Methods Investigators reported a series of cases of patients who received oral mesalazine1g qid for hidradenitis suppurativa in our institution between May 2020 and September 2023 A total of 27 patients 22 in the mild to moderate group and 5 in the severe group were included in this study
Objective To evaluate the efficacy and safety of oral mesalazine treatment for hidradenitis suppurativa
Methods Investigators reported a series of cases of patients who received oral mesalazine1g qid for hidradenitis suppurativa in our institution between May 2020 and September 2023 A total of 27 patients 22 in the mild to moderate group and 5 in the severe group were included in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None